Vertex Pharmaceuticals Shares Are Up Today: What's Going On?
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...
BioWorld18m
Vertex wins FDA nod for Journavx, new mechanism for acute pain
An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...
Vertex Pharmaceuticals price target raised to $545 from $520 at BMO Capital
BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform ...
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion
Vertex Pharmaceuticals has agreed to acquire Alpine ... The acquisition is the largest in Vertex’s history, a ...
AFP16h
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
Vertex Pharmaceuticals price target raised to $433 from $430 at Scotiabank
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $433 from $430 and keeps a Sector Perform rating on the shares.
Vertex Pharmaceuticals (NASDAQ:VRTX) lifts 3.2% this week, taking five-year gains to 83%
The simplest way to invest in stocks is to buy exchange traded funds. But you can do a lot better than that by ...